Your browser doesn't support javascript.
loading
Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma.
Crippa, Stefano; Pergolini, Ilaria; Javed, Ammar A; Honselmann, Kim C; Weiss, Matthew J; Di Salvo, Francesca; Burkhart, Richard; Zamboni, Giuseppe; Belfiori, Giulio; Ferrone, Cristina R; Rubini, Corrado; Yu, Jun; Gasparini, Giulia; Qadan, Motaz; He, Jin; Lillemoe, Keith D; Castillo, Carlos Fernandez-Del; Wolfgang, Christopher L; Falconi, Massimo.
Afiliación
  • Crippa S; School of Medicine, Vita-Salute San Raffaele University, Division of Pancreatic Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Pergolini I; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Javed AA; Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Honselmann KC; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Weiss MJ; Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Di Salvo F; School of Medicine, Vita-Salute San Raffaele University, Division of Pancreatic Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Burkhart R; Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Zamboni G; Department of Pathology, Ospedale Sacro Cuore-Don Calabria, Negrar, Italy.
  • Belfiori G; School of Medicine, Vita-Salute San Raffaele University, Division of Pancreatic Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Ferrone CR; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Rubini C; Department of Pathology, Universita` Politecnica delle Marche, Ospedali Riuniti, Ancona, Italy.
  • Yu J; Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Gasparini G; School of Medicine, Vita-Salute San Raffaele University, Division of Pancreatic Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Qadan M; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • He J; Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Lillemoe KD; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Castillo CF; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Wolfgang CL; Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Falconi M; School of Medicine, Vita-Salute San Raffaele University, Division of Pancreatic Surgery, Pancreas Translational & Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Ann Surg ; 276(2): 378-385, 2022 08 01.
Article en En | MEDLINE | ID: mdl-33086324
OBJECTIVE: To describe PNI and to evaluate its impact on disease-free (DFS) and overall survival (OS) in patients with resected pancreatic ductal adenocarcinoma (PDAC). SUMMARY OF BACKGROUND DATA: Although PNI is a prognostic factor for survival in many GI cancers, there is limited knowledge regarding its impact on tumor recurrence, especially in ''early stage disease'' (PDAC ≤20 mm, R0/ N0 PDAC). METHODS: This multicenter retrospective study included patients undergoing PDAC resection between 2009 and 2014. The association of PNI with DFS and OS was analyzed using Cox proportional-hazards models. RESULTS: PNI was found in 87% of 778 patients included in the study, with lower rates in PDAC ≤20 mm (78.7%) and in R0/N0 tumors (70.6%). PNI rate did not differ between patients who underwent neoadjuvant therapy and upfront surgery (88% vs 84%, P = 0.08). Although not significant at multivariate analysis ( P = 0.07), patients with PNI had worse DFS at univariate analysis (median DFS: 20 vs 15 months, P < 0.01). PNI was the only independent predictor of DFS in R0/N0 tumors (hazard ratio [HR]: 2.2) and in PDAC ≤ 20 mm (HR: 1.8). PNI was an independent predictor of OS in the entire cohort (27 vs 50 months, P = 0.01), together with G3 tumors, pN1 status, carbohydrate antigen (CA) 19.9 >37 and pain. CONCLUSIONS: PNI represents a major determinant of tumor recurrence and patients' survival in pancreatic cancer. The role of PNI is particularly relevant in early stages, supporting the hypothesis that invasion of nerves by cancer cells has a driving role in pancreatic cancer progression.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Ann Surg Año: 2022 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Carcinoma Ductal Pancreático Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Ann Surg Año: 2022 Tipo del documento: Article País de afiliación: Italia